FDA will review Eisai and Biogen’s Alzheimer’s treatment Leqembi with decision on full approval expected in early July.
Exelixis, Inc. today announced that the phase 3 CONTACT-03 study did not meet its primary endpoint of progression-free survival (PFS).
The US government contributed at least $31.9 billion in public funding to the development of mRNA-based Covid-19 vaccines, according to a new BMJ study.
Reata Pharmaceuticals is aiming to make the drug omaveloxolone available by the second quarter of 2023.
We use cookies only to remember your preferences and provide better browsing experience. We do not sell user information. Here is our privacy policy.